Akoya Biosciences Cuts FY24 Revenue Forecast From $114M-$118M To $104M-$112M, Est $115.767M
Portfolio Pulse from Benzinga Newsdesk
Akoya Biosciences has revised its FY24 revenue forecast downwards from $114M-$118M to $104M-$112M, against an estimated $115.767M, while still aiming for operating cash flow breakeven by year end.
May 13, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akoya Biosciences lowers its FY24 revenue forecast, indicating potential challenges ahead but maintains its goal for cash flow breakeven.
Lowering the revenue forecast can often lead to negative investor sentiment as it may indicate underlying challenges in the company's operations or market conditions. However, the commitment to achieving cash flow breakeven by year-end might mitigate some concerns, indicating management's confidence in operational efficiency and cost control.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100